Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (NCT05283330)
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors
🩺 Plain-English Summary (8th-Grade Level)
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Who can join: Review the eligibility criteria below.
Location: Northwestern University Robert H Lurie Medical Research — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Northwestern University Robert H Lurie Medical Research — Chicago, Illinois
- University of Iowa Health Care — Iowa City, Iowa
- UK Markey Cancer Center — Lexington, Kentucky
- Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland
- United Theranostics - Chesapeake — Glen Burnie, Maryland
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) — Omaha, Nebraska
- XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
- University of Pittsburg Medical Center (UPCM) — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (469) 638-0744
Email: clinicaltrials@oranomed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cervical Cancer
- SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study) — Ouagadougou,
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — Boston, Massachusetts
- International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer — Liège,
- Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement — Houston, Texas
- Sexual Health Empowerment for Women's Health — Kansas City, Missouri
- Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique — Houston, Texas
Explore by condition: All Cervical Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.